DK0721501T3 - Farmaceutisk præparat der omfatter phosphatase eller et derivat deraf - Google Patents

Farmaceutisk præparat der omfatter phosphatase eller et derivat deraf

Info

Publication number
DK0721501T3
DK0721501T3 DK94927860T DK94927860T DK0721501T3 DK 0721501 T3 DK0721501 T3 DK 0721501T3 DK 94927860 T DK94927860 T DK 94927860T DK 94927860 T DK94927860 T DK 94927860T DK 0721501 T3 DK0721501 T3 DK 0721501T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
endotoxin
relates
bone
phosphatase
Prior art date
Application number
DK94927860T
Other languages
English (en)
Inventor
Klaas Poelstra
Machiel Josephus Hardonk
Winston Willem Bakker
Dirk Klaas Fokke Meijer
Original Assignee
Pharmaaware Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaaware Ip B V filed Critical Pharmaaware Ip B V
Application granted granted Critical
Publication of DK0721501T3 publication Critical patent/DK0721501T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
DK94927860T 1993-08-13 1994-08-10 Farmaceutisk præparat der omfatter phosphatase eller et derivat deraf DK0721501T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL1993/000171 WO1995005455A1 (en) 1993-08-13 1993-08-13 Pharmaceutical composition comprising phosphatase or a derivative thereof
PCT/NL1994/000189 WO1995005456A1 (en) 1993-08-13 1994-08-10 Pharmaceutical composition comprising phosphatase or a derivative thereof

Publications (1)

Publication Number Publication Date
DK0721501T3 true DK0721501T3 (da) 2005-08-29

Family

ID=19861990

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927860T DK0721501T3 (da) 1993-08-13 1994-08-10 Farmaceutisk præparat der omfatter phosphatase eller et derivat deraf

Country Status (10)

Country Link
US (1) US6290952B1 (da)
EP (1) EP0721501B1 (da)
JP (1) JP3835811B2 (da)
AT (1) ATE298790T1 (da)
AU (3) AU4835693A (da)
DE (1) DE69434414T2 (da)
DK (1) DK0721501T3 (da)
ES (1) ES2244956T3 (da)
PT (1) PT721501E (da)
WO (2) WO1995005455A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177666T3 (es) 1995-05-25 2002-12-16 Ngk Insulators Ltd Remedio para la endotoxinemia y disfunciones de organos multiples inducidos por la misma.
EP1141717A1 (en) * 1998-12-21 2001-10-10 Stichting voor de Technische Wetenschappen Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US7888372B2 (en) * 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
US7048914B2 (en) * 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
AU2003298036A1 (en) * 2002-12-12 2004-07-09 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
CA2554683C (en) 2004-02-04 2014-06-10 Pharmaaware Sepsis B.V. Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
DE602005027461D1 (de) * 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2007075343A2 (en) * 2005-12-15 2007-07-05 Chemgen Corporation Enzymes for reduced immunological stress
WO2007075199A1 (en) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
EP1985697A1 (en) * 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
US8784805B2 (en) 2008-02-29 2014-07-22 Alloksys Life Sciences B.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
WO2010025267A2 (en) * 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
US8932587B2 (en) 2010-02-12 2015-01-13 The General Hospital Corporation Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc. métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
EP2620162A1 (de) 2012-01-27 2013-07-31 Life Science Inkubator Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9926544B2 (en) 2014-01-24 2018-03-27 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
EP3097188B1 (en) 2014-01-24 2018-08-29 AM-Pharma B.V. Downstream processing of an alkaline phosphatase
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20240160671A (ko) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
WO2018175413A1 (en) 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
JP7526737B2 (ja) * 2019-03-06 2024-08-01 ガンブロ ルンディア アクティエボラーグ アルカリホスファターゼを含む血液処理装置
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
WO2020243697A1 (en) 2019-05-31 2020-12-03 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
US11103628B1 (en) * 2020-04-29 2021-08-31 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US10881781B1 (en) 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166766A (en) * 1976-08-09 1979-09-04 Wisconsin Alumni Research Foundation Method for quantitative assay of alkaline phosphatase isoenzymes in serum
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL58421A (en) * 1979-10-09 1984-01-31 Yeda Res & Dev Production of(2'-5')oligoisoadenylate and pharmaceutical compositions containing it
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4720458A (en) * 1983-10-19 1988-01-19 Sullivan Cornelius W Heat sensitive bacterial alkaline phosphatase
US4782016A (en) * 1985-01-18 1988-11-01 Eastman Kodak Company Analytical element and method for determination of theophylline by enzyme inhibition
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5017501A (en) * 1987-11-25 1991-05-21 Abbott Laboratories Preparation of uniformly sized liposomes encapsulating an aqueous liquid
US4873035A (en) * 1987-11-25 1989-10-10 Abbott Laboratories Preparation of sized populations of liposomes
GB8822738D0 (en) * 1988-09-28 1988-11-02 Medisense Inc Theophylline assay
ATE157702T1 (de) * 1990-02-07 1997-09-15 Abbott Lab Alkalische phosphatase mit verbesserter spezifischer aktivität zur verwendung in indikatorreagenzien
EP0525188B1 (en) * 1990-04-18 1995-03-01 Takeda Chemical Industries, Ltd. Liposome composition
NL9100434A (nl) * 1991-03-11 1992-10-01 Rijksuniversiteit Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan.
JPH06508780A (ja) * 1991-07-11 1994-10-06 ビーティージー・インターナショナル・リミテッド 移植片材料
US5248590A (en) * 1991-07-22 1993-09-28 Becton, Dickinson And Company Surface modified liposomes
US5413924A (en) * 1992-02-13 1995-05-09 Kosak; Kenneth M. Preparation of wax beads containing a reagent for release by heating

Also Published As

Publication number Publication date
WO1995005456A1 (en) 1995-02-23
ATE298790T1 (de) 2005-07-15
ES2244956T3 (es) 2005-12-16
JP3835811B2 (ja) 2006-10-18
AU1424399A (en) 1999-04-01
WO1995005455A1 (en) 1995-02-23
EP0721501B1 (en) 2005-06-29
AU4835693A (en) 1995-03-14
DE69434414T2 (de) 2006-05-18
US6290952B1 (en) 2001-09-18
AU7710194A (en) 1995-03-14
DE69434414D1 (de) 2005-08-04
EP0721501A1 (en) 1996-07-17
JPH09502342A (ja) 1997-03-11
PT721501E (pt) 2005-11-30
AU698331B2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
DK0721501T3 (da) Farmaceutisk præparat der omfatter phosphatase eller et derivat deraf
AU560251B2 (en) Pharmaceutical compositions of mopidamol
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
MY111188A (en) Improvements in or relating to benzothiophenes.
DE69109376D1 (de) Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines.
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
PT100850A (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
PL330865A1 (en) Agents containing lectins and their application
ATE485818T1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
DE59204543D1 (de) Chenodeoxycholsäure oder Ursodeoxycholsäure zur Behandlung von Erkrankungen der Atmungsorgane.
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
PT994884E (pt) Sais de acido difosfonico para o tratamento da osteoporose
ATE234862T1 (de) Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen
DE59508366D1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
MX9304925A (es) Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.
DE68919673D1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DK0585371T3 (da) Aromatiske oligomere forbindelser, som er anvendelige til at imitere bioaktive makromolekyler
ZA966953B (en) Pharmaceutical composition.
SE8403659D0 (sv) Synergistic pharmaceutical composition
DK0655251T3 (da) Farmaceutisk præparat til forebyggelse eller behandling af knoglebrud